Hans Schreiber to Neoplasms, Experimental
This is a "connection" page, showing publications Hans Schreiber has written about Neoplasms, Experimental.
Connection Strength
6.298
-
Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2022 02; 74:25-31.
Score: 0.696
-
Tumor-associated fibroblasts predominantly come from local and not circulating precursors. Proc Natl Acad Sci U S A. 2016 07 05; 113(27):7551-6.
Score: 0.482
-
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter. Cancer Res. 2014 Jan 15; 74(2):632; discussion 635.
Score: 0.407
-
Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol. 2014 Feb 01; 192(3):1286-93.
Score: 0.406
-
Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res. 2012 May 01; 18(9):2526-33.
Score: 0.359
-
Densely granulated murine NK cells eradicate large solid tumors. Cancer Res. 2012 Apr 15; 72(8):1964-74.
Score: 0.358
-
Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes. Cancer Immun. 2011 Jun 30; 11:2.
Score: 0.342
-
Cancer. Awakening immunity. Science. 2010 Nov 05; 330(6005):761-2.
Score: 0.327
-
Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med. 2010 Oct 25; 207(11):2469-77.
Score: 0.325
-
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007 Jan 22; 204(1):49-55.
Score: 0.251
-
Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18. J Immunol. 2004 Mar 01; 172(5):3243-51.
Score: 0.206
-
Bystander elimination of antigen loss variants in established tumors. Nat Med. 2004 Mar; 10(3):294-8.
Score: 0.205
-
Genetic changes occurring in established tumors rapidly stimulate new antibody responses. Proc Natl Acad Sci U S A. 2003 Apr 29; 100(9):5425-30.
Score: 0.193
-
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 2002 Dec; 17(6):737-47.
Score: 0.188
-
Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors. Cancer Immunol Res. 2020 02; 8(2):192-202.
Score: 0.153
-
Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med. 1997 Jul 21; 186(2):229-38.
Score: 0.130
-
Radiation can inhibit tumor growth indirectly while depleting circulating leukocytes. Radiat Res. 1996 Dec; 146(6):612-8.
Score: 0.124
-
Inhibition of tumor growth by elimination of granulocytes. J Exp Med. 1995 Jan 01; 181(1):435-40.
Score: 0.109
-
Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes. Eur J Immunol. 1993 Nov; 23(11):2770-6.
Score: 0.100
-
Prevention of runting and cachexia by a chimeric TNF receptor-Fc protein. Clin Immunol Immunopathol. 1993 Nov; 69(2):215-22.
Score: 0.100
-
A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med. 1993 Sep 01; 178(3):933-40.
Score: 0.099
-
Genetically engineered vaccines. Comparison of active versus passive immunotherapy against solid tumors. Ann N Y Acad Sci. 1993 Aug 12; 690:244-55.
Score: 0.099
-
CD4-positive and B lymphocytes in transplantation immunity. I. Promotion of tumor allograft rejection through elimination of CD4-positive lymphocytes. Transplantation. 1993 Jun; 55(6):1349-55.
Score: 0.098
-
MHC class I restricted T cells and immune surveillance against transplanted ultraviolet light-induced tumors. Semin Cancer Biol. 1991 Oct; 2(5):321-8.
Score: 0.087
-
Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci U S A. 1991 May 01; 88(9):3535-9.
Score: 0.084
-
Highly immunogenic regressor tumor cells can prevent development of postsurgical tumor immunity. Cell Immunol. 1989 Mar; 119(1):101-13.
Score: 0.073
-
Identification of a gene encoding a tumor-specific antigen that causes tumor rejection. Haematol Blood Transfus. 1987; 31:308-13.
Score: 0.063
-
Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res. 2002 Oct 15; 62(20):5792-9.
Score: 0.047
-
Tracking the common ancestry of antigenically distinct cancer variants. Clin Cancer Res. 2001 Mar; 7(3 Suppl):871s-875s.
Score: 0.042
-
Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. Int J Oncol. 1999 Oct; 15(4):769-73.
Score: 0.038
-
The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med. 1997 Feb 17; 185(4):695-705.
Score: 0.032
-
CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation. 1993 Jun; 55(6):1356-61.
Score: 0.024
-
Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice. J Immunol. 1990 Apr 01; 144(7):2840-6.
Score: 0.020
-
In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science. 1988 Oct 28; 242(4878):569-71.
Score: 0.018
-
Relationship of tumour necrosis factor and endotoxin to macrophage cytotoxicity, haemorrhagic necrosis and lethal shock. Ciba Found Symp. 1987; 131:124-39.
Score: 0.016